The FDA on November 16, 2023, approved XTANDI® for non-metastatic Castration-Sensitive Prostate Cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). XTANDI® is a product of Astellas Pharma US, Inc.
Other Pages – Top Ad
Advertisement